TBKBP1 induces capecitabine resistance through negative regulation of type I interferon pathway in triple-negative breast cancer.

ABSTRACT: Capecitabine has been commonly used for the treatment of early-stage triple-negative breast cancer (TNBC) patients; however, the resistance limits its curative potential. Here, we perform multi-omics data analysis and immunohistochemical (IHC) staining of biological samples from patients in the CBCSG010 clinical trial who were randomized to receive adjuvant docetaxel-anthracycline-based chemotherapy with or without capecitabine. We find that patients with a better prognosis in the capecitabine group exhibited an immune-inflamed microenvironment and upregulation of interferon pathways. Moreover, we identify interferon-related TANK-binding kinase 1-binding protein 1 (TBKBP1) as the key gene involved in capecitabine resistance. We uncover that TBKBP1 promotes capecitabine resistance through i

SUBMITTER: Wu WY 

PROVIDER: S-EPMC12867762 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature